Mersana Therapeutics (MRSN)
(Real Time Quote from BATS)
$2.17 USD
-0.05 (-2.25%)
Updated Jun 14, 2024 11:28 AM ET
3-Hold of 5 3
F Value D Growth F Momentum F VGM
Brokerage Reports
Mersana Therapeutics, Inc. [MRSN]
Reports for Purchase
Showing records 181 - 199 ( 199 total )
Company: Mersana Therapeutics, Inc.
Industry: Unclassified
Continuing Dose Escalation Evidence of 1522?s Favorable Tolerability Profile
Provider: WEDBUSH SECURITIES INC.
Analyst: NIERENGARTEN D
Company: Mersana Therapeutics, Inc.
Industry: Unclassified
HEALTHCARE - The Week Ahead in Life Sciences
Provider: WEDBUSH SECURITIES INC.
Analyst: NIERENGARTEN D
Company: Mersana Therapeutics, Inc.
Industry: Unclassified
ADCs Are Not Created Equal; Peer Issues Have No Readthrough to Mersana
Provider: H.C. Wainwright & Co., Inc.
Analyst: CHATTOPADHYAY D
Company: Mersana Therapeutics, Inc.
Industry: Unclassified
Thinking Beyond Monotherapy; Mersana at the AACR
Provider: H.C. Wainwright & Co., Inc.
Analyst: CHATTOPADHYAY D
Company: Mersana Therapeutics, Inc.
Industry: Unclassified
Two Differentiated Programs Approaching Validation; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: CHATTOPADHYAY D
Company: Mersana Therapeutics, Inc.
Industry: Unclassified
4Q, MTD Not Yet Reached for 1522, Reflecting Good Tolerability
Provider: WEDBUSH SECURITIES INC.
Analyst: NIERENGARTEN D
Company: Mersana Therapeutics, Inc.
Industry: Unclassified
Company: Mersana Therapeutics, Inc.
Industry: Unclassified
If a DAR of Seven Is Good, Could 12 Be Better? This Is the Crux of Our Bullish Thesis
Provider: H.C. Wainwright & Co., Inc.
Analyst: CHATTOPADHYAY D
Company: Mersana Therapeutics, Inc.
Industry: Unclassified
Company: Mersana Therapeutics, Inc.
Industry: Unclassified
Bad Optics Yes, But We Don?t Think There''s Anything Sinister Behind the CMO?s Departure
Provider: H.C. Wainwright & Co., Inc.
Analyst: CHATTOPADHYAY D
Company: Mersana Therapeutics, Inc.
Industry: Unclassified
One Small Step for DAR''s, One Giant Leap for ADC''s; Initiating With a Buy Rating and $33 Target
Provider: H.C. Wainwright & Co., Inc.
Analyst: CHATTOPADHYAY D
Company: Mersana Therapeutics, Inc.
Industry: Unclassified
HEALTHCARE - The Week Ahead in Life Sciences
Provider: WEDBUSH SECURITIES INC.
Analyst: NIERENGARTEN D
Company: Mersana Therapeutics, Inc.
Industry: Unclassified
HEALTHCARE - The Week Ahead in Life Sciences
Provider: WEDBUSH SECURITIES INC.
Analyst: NIERENGARTEN D
Company: Mersana Therapeutics, Inc.
Industry: Unclassified
MORNING CALL
Provider: WEDBUSH SECURITIES INC.
Company: Mersana Therapeutics, Inc.
Industry: Unclassified
Company: Mersana Therapeutics, Inc.
Industry: Unclassified
XMT-1536 IND Cleared, Triple Meeting Highlights Potential in Ovarian Cancer
Provider: WEDBUSH SECURITIES INC.
Analyst: NIERENGARTEN D
Company: Mersana Therapeutics, Inc.
Industry: Unclassified
MORNING CALL
Provider: WEDBUSH SECURITIES INC.
Company: Mersana Therapeutics, Inc.
Industry: Unclassified
MORNING CALL
Provider: WEDBUSH SECURITIES INC.
Company: Mersana Therapeutics, Inc.
Industry: Unclassified
Initiating Coverage at OUTPERFORM; Unlocking the Potential of ADCs
Provider: WEDBUSH SECURITIES INC.
Analyst: NIERENGARTEN D